Atlas Trials

Azidus Brasil

80 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Azidus Brasil

RecordFirmDate
IVIG Boya: Safety, Efficacy, and Pharmacokinetics (NCT06150833)Azidus Brasil2026-09-01
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza (NCT06817096)Azidus Brasil2025-02-01
Safety of UFRJvac, Trivalent COVID-19 Vaccine (NCT06303635)Azidus Brasil2024-06-24
Efficacy and Safety of NestaCell® in Huntington's Disease (NCT06097780)Azidus Brasil2024-06-08
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG (NCT06089122)Azidus Brasil2024-04-01
Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine (NCT05542693)Azidus Brasil2023-01-01
Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19 (NCT04423861)Azidus Brasil2022-06-22
Study To Evaluate The Sensitivity Of The Linda Thermal Device (NCT05009277)Azidus Brasil2021-08-30
Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients (NCT04441398)Azidus Brasil2020-07-01
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (NCT04315987)Azidus Brasil2020-06-30
Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 (NCT04435314)Azidus Brasil2020-06-01
Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients (NCT04352465)Azidus Brasil2020-05-01
Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19 (NCT04329572)Azidus Brasil2020-04-23
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19 (NCT04348474)Azidus Brasil2020-04-20
Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. (NCT04219241)Azidus Brasil2020-02-10
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease (NCT03252535)Azidus Brasil2018-01-15
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease (NCT02728115)Azidus Brasil2017-10-16

Track Azidus Brasil automatically

Every clearance here is in the API, with alerts when new ones post.